Global Custom Market Research Reports Provider Company

phone

Alnylam Pharmaceuticals Inc (ALNY) - Financial and Strategic SWOT Analysis Review

  • Published Date: 05 Jul 2018
  • Number of Pages: 56
  • Category: SWOT Analysis
  • Country: United States of America
Alnylam Pharmaceuticals Inc (ALNY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Alnylam Pharmaceuticals Inc, (Alnylam) is a biopharmaceutical company which discovers, develops and commercializes therapeutics based on Ribo Nucleic Acid interference (RNAi). The company offers a broad pipeline of investigational RNAi therapeutics in the areas of genetic medicines; cardiovascular and metabolic disease; and hepatic infectious disease. It also offers Alnylam 5x15 program for advancing genetically defined disease targets for the treatment of respiratory syncytial virus and liver cancer. Alnylam employs lipid nanoparticles for intravenous systemic delivery of sRNAi to right body organs and cells so that it could trigger the RNAi mechanism. The company works in partnership with Merck, Medtronic, Roche, Novartis, Biogen, Takeda, Cubist, GlaxoSmithKline, Ascletis, The Medicines Company, Kyowa Hakko Kirin, Monsanto, and Sanofi Genzyme for advancing its RNAi therapeutics. Alnylam is headquartered in Cambridge, Massachusetts, the US.

Alnylam Pharmaceuticals Inc Key Recent Developments

Jun 20,2018: Alnylam Pharmaceuticals Announces Senior Management Changes
May 15,2018: Alnylam Appoints Colleen Reitan to the Board of Directors
May 08,2018: Alnylam Reports Preclinical Data Demonstrating Central Nervous System (CNS) Delivery of RNAi Therapeutics
May 03,2018: Alnylam Pharmaceuticals Reports First Quarter 2018 Financial Results and Highlights Recent Period Activity
Apr 20,2018: Alnylam Reaches Settlement Agreement with Dicerna Pharmaceuticals Resolving Trade Secret Misappropriation and Other Pending Litigation

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
Publisher Name : GlobalData


List of Tables 5
List of Figures 5
Section 1 - About the Company 6
Alnylam Pharmaceuticals Inc - Key Facts 6
Alnylam Pharmaceuticals Inc - Key Employees 7
Alnylam Pharmaceuticals Inc - Key Employee Biographies 9
Alnylam Pharmaceuticals Inc - Major Products and Services 10
Alnylam Pharmaceuticals Inc - History 11
Alnylam Pharmaceuticals Inc - Company Statement 16
Alnylam Pharmaceuticals Inc - Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Joint Venture 18
Section 2 Company Analysis 19
Company Overview 19
Alnylam Pharmaceuticals Inc - Business Description 20
Alnylam Pharmaceuticals Inc - Corporate Strategy 21
Alnylam Pharmaceuticals Inc - SWOT Analysis 22
SWOT Analysis - Overview 22
Alnylam Pharmaceuticals Inc - Strengths 22
Alnylam Pharmaceuticals Inc - Weaknesses 23
Alnylam Pharmaceuticals Inc - Opportunities 24
Alnylam Pharmaceuticals Inc - Threats 25
Alnylam Pharmaceuticals Inc - Key Competitors 26
Section 3 Company Financial Ratios 27
Financial Ratios - Capital Market Ratios 27
Financial Ratios - Annual Ratios 28
Performance Chart 30
Financial Performance 30
Financial Ratios - Interim Ratios 31
Financial Ratios - Ratio Charts 32
Section 4 Companys Lifesciences Financial Deals and Alliances 33
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 33
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 34
Alnylam Pharmaceuticals Inc, Recent Deals Summary 35
Section 5 Companys Recent Developments 36
May 15, 2018: Alnylam Appoints Colleen Reitan to the Board of Directors 36
May 08, 2018: Alnylam Reports Preclinical Data Demonstrating Central Nervous System (CNS) Delivery of RNAi Therapeutics 37
May 03, 2018: Alnylam Pharmaceuticals Reports First Quarter 2018 Financial Results and Highlights Recent Period Activity 38
Apr 20, 2018: Alnylam Reaches Settlement Agreement with Dicerna Pharmaceuticals Resolving Trade Secret Misappropriation and Other Pending Litigation 41
Apr 20, 2018: Dicerna Pharmaceuticals Announces Settlement of All Litigation with Alnylam 42
Mar 21, 2018: Regeneron Genetics Center Publication in New England Journal of Medicine Identifies New Genetic Variant Providing Protection from Chronic Liver Disease 43
Feb 08, 2018: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Period Activity 45
Jan 10, 2018: Regeneron forms consortium to advance human gene sequencing 48
Jan 10, 2018: Regeneron forms consortium to advance human gene sequencing 49
Jan 07, 2018: Alnylam Announces 2018 Corporate Goals 50
Section 6 Appendix 52
Methodology 52
Ratio Definitions 52
About GlobalData 56
Contact Us 56
Disclaimer 56

List Of Tables

List of Tables
Alnylam Pharmaceuticals Inc, Key Facts 6
Alnylam Pharmaceuticals Inc, Key Employees 7
Alnylam Pharmaceuticals Inc, Key Employee Biographies 9
Alnylam Pharmaceuticals Inc, Major Products and Services 10
Alnylam Pharmaceuticals Inc, History 11
Alnylam Pharmaceuticals Inc, Subsidiaries 17
Alnylam Pharmaceuticals Inc, Joint Venture 18
Alnylam Pharmaceuticals Inc, Key Competitors 26
Alnylam Pharmaceuticals Inc, Ratios based on current share price 27
Alnylam Pharmaceuticals Inc, Annual Ratios 28
Alnylam Pharmaceuticals Inc, Annual Ratios (Cont...1) 29
Alnylam Pharmaceuticals Inc, Interim Ratios 31
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 33
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 34
Alnylam Pharmaceuticals Inc, Recent Deals Summary 35
Currency Codes 52
Capital Market Ratios 52
Equity Ratios 53
Profitability Ratios 53
Cost Ratios 54
Liquidity Ratios 54
Leverage Ratios 55
Efficiency Ratios 55

List Of Figures

List of Figures
Alnylam Pharmaceuticals Inc, Performance Chart (2013 - 2017) 30
Alnylam Pharmaceuticals Inc, Ratio Charts 32
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 33
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 34

Alnylam Pharmaceuticals Inc (ALNY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by

View Report

Alnylam Pharmaceuticals Inc, (Alnylam) is a biopharmaceutical company which discovers, develops and commercializes therapeutics based on Ribo Nucleic Acid interference (RNAi). The company offers a broad pipeline of investigational RNAi

View Report

Alnylam Pharmaceuticals Inc, (Alnylam) is a biopharmaceutical company which discovers, develops and commercializes therapeutics based on Ribo Nucleic Acid interference (RNAi). The company offers a broad pipeline of investigational RNAi

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports